Acumen Pharmaceuticals Inc
ABOS1.900USD
-0.130-6.40%
收盘 11/06, 16:00（美东）报价延迟15分钟
115.09M总市值
亏损市盈率 TTM
关于 Acumen Pharmaceuticals Inc 公司
Acumen Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司致力于开发一种针对阿尔茨海默病 (AD) 根本病因的疾病改良方法。该公司专注于推进靶向免疫治疗候选药物 sabirnetug (ACU193) 的临床开发，该药物在早期 AD 患者（因阿尔茨海默病病理而患有轻度认知障碍或轻度痴呆的患者）的 I 期结果发布后进入临床开发阶段。Sabirnetug 是一种重组人源化免疫球蛋白γ2 (IgG2) 单克隆抗体 (mAb)，可选择性靶向抗淀粉样蛋白-β寡聚体 (AbOs)，在体外试验中已证明具有功能性和保护作用，并在多种动物物种（包括 AD 的转基因模型）中证明了体内安全性和药理活性。该公司正在开发用于静脉 (IV) 给药的 sabirnetug，每四周给药一次，用于治疗早期 AD。
Acumen Pharmaceuticals Inc简介
公司代码ABOS
公司名称Acumen Pharmaceuticals Inc
上市日期Jul 01, 2021
CEOMr. Daniel J. (Dan) O'Connell
员工数量61
证券类型Ordinary Share
年结日Jul 01
公司地址1210-1220 Washington Street
城市NEWTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02465
电话16173444190
网址https://acumenpharm.com/
公司代码ABOS
上市日期Jul 01, 2021
CEOMr. Daniel J. (Dan) O'Connell
Acumen Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Chairman of the Board
Independent Chairman of the Board
316.72K
+4.21%
Mr. Russell Barton
Mr. Russell Barton
Chief Operating Officer
Chief Operating Officer
136.12K
+40.52%
Dr. Nathan B. Fountain, M.D.
Dr. Nathan B. Fountain, M.D.
Independent Director
Independent Director
19.05K
+204.80%
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
12.80K
--
Mr. Daniel J. (Dan) O'Connell
Mr. Daniel J. (Dan) O'Connell
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. James (Jim) Doherty, Ph.D.
Dr. James (Jim) Doherty, Ph.D.
President, Chief Development Officer
President, Chief Development Officer
--
--
Dr. Amy Schacterle, Ph.D.
Dr. Amy Schacterle, Ph.D.
Chief Regulatory Officer, Head of Quality
Chief Regulatory Officer, Head of Quality
--
--
Dr. Jeffrey L. (Jeff) Ives, Ph.D.
Dr. Jeffrey L. (Jeff) Ives, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Derek Meisner, J.D.
Mr. Derek Meisner, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Sean Stalfort
Mr. Sean Stalfort
Independent Chairman of the Board
Independent Chairman of the Board
316.72K
+4.21%
Mr. Russell Barton
Mr. Russell Barton
Chief Operating Officer
Chief Operating Officer
136.12K
+40.52%
Dr. Nathan B. Fountain, M.D.
Dr. Nathan B. Fountain, M.D.
Independent Director
Independent Director
19.05K
+204.80%
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
12.80K
--
Mr. Daniel J. (Dan) O'Connell
Mr. Daniel J. (Dan) O'Connell
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. James (Jim) Doherty, Ph.D.
Dr. James (Jim) Doherty, Ph.D.
President, Chief Development Officer
President, Chief Development Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月24日 周五
更新时间: 10月24日 周五
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
24.65%
Hardie Robert D
5.70%
Sands Capital Ventures LLC
5.64%
PBM Capital Group, LLC
5.29%
Franklin Advisers, Inc.
3.81%
其他
54.91%
持股股东
持股股东
占比
RA Capital Management, LP
24.65%
Hardie Robert D
5.70%
Sands Capital Ventures LLC
5.64%
PBM Capital Group, LLC
5.29%
Franklin Advisers, Inc.
3.81%
其他
54.91%
股东类型
持股股东
占比
Venture Capital
29.94%
Hedge Fund
16.95%
Investment Advisor
11.09%
Individual Investor
7.31%
Investment Advisor/Hedge Fund
6.54%
Research Firm
1.84%
Family Office
1.75%
其他
24.59%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
205
40.21M
66.38%
-14.32M
2025Q2
213
49.42M
81.58%
-13.01M
2025Q1
216
49.81M
82.34%
-14.19M
2024Q4
212
52.16M
86.83%
-12.81M
2024Q3
210
53.44M
88.96%
-11.71M
2024Q2
204
53.38M
88.87%
-9.85M
2024Q1
207
53.65M
94.74%
-5.72M
2023Q4
196
47.92M
87.62%
-10.56M
2023Q3
182
52.56M
97.69%
+4.27M
2023Q2
168
35.68M
86.97%
-7.58M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
14.93M
24.65%
--
--
Jun 30, 2025
Hardie Robert D
3.45M
5.7%
--
--
Apr 08, 2025
Sands Capital Ventures LLC
3.42M
5.64%
--
--
Jun 30, 2025
PBM Capital Group, LLC
3.21M
5.29%
--
--
Apr 08, 2025
Franklin Advisers, Inc.
3.05M
5.04%
-63.10K
-2.02%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.03M
3.35%
+4.11K
+0.20%
Jun 30, 2025
Millennium Management LLC
1.95M
3.22%
+814.90K
+71.78%
Jun 30, 2025
The Vanguard Group, Inc.
1.69M
2.79%
-247.64K
-12.78%
Jun 30, 2025
Knollwood Investment Advisory, LLC
1.63M
2.69%
--
--
Jun 30, 2025
Pathstone
1.06M
1.75%
-28.00K
-2.58%
Jun 30, 2025
查看更多
持股ETF
更新时间: 18 小时前
更新时间: 18 小时前
机构名称
占比
iShares Micro-Cap ETF
0.01%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Micro-Cap ETF
占比0.01%
ProShares Hedge Replication ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 2000 ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Global X Russell 2000 ETF
占比0%
iShares Neuroscience and Healthcare ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
